Global Osteoporosis Drugs Market (Size of $8,835.4 million in 2015) to Witness 3.8% CAGR During 2016 – 2022

  • Published: July 2016

The global osteoporosis drugs market is expected to generate $11,482.1 million revenue by 2022, with a CAGR of 3.8% during the forecast period (2016–2022). Some of the notable factors responsible for the market growth are increasing research and development (R&D) activities by market players, growing healthcare expenditure, and rising occurrence of osteoporosis in females in post-menopausal phase.

Osteoporosis is a very common bone disease, which is responsible for the degradation of mineral density in bones, and can often lead to risk of fractures and tender bones in patients. The disease is known to lead to the weakening of bones in the patients. The people aged 65 years and above are at high risk of shoulder and forearm fractures, which are one of the most common symptoms of this disease. The disease is basically diagnosed through traditional radiography tests and X-ray examination. Further, it is believed that proper diet along with medications is successful in the management of the disease.

Based on drug class, the osteoporosis drugs market is categorized into bisphosphonates, parathyroid hormone therapy, selective estrogen receptor modulator (SERM), rank ligand inhibitor, and calcitonin. Among these, the bisphosphonates category held the largest share in the market in 2015; whereas, the rank ligand inhibitor category is expected to witness the fastest growth during the forecast period.

Globally, North America holds a leading position in the osteoporosis drugs market. Whereas, the Asia-Pacific (APAC) market is expected to register the fastest growth, with a CAGR of 4.2%, during the forecast period, mainly on account of the factors such as growing healthcare expenditure and rising awareness about the disease.

Although the osteoporosis drugs market is likely to witness growth in the coming years, but factors such as stringent regulations, patent expiration, and harmful effects of drugs may impede the growth of the market in the coming years.

Some of the key companies operating in the global osteoporosis drugs market are Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc., and Amgen Inc.


Market Segmentation by Drug Class

  • Bisphosphonates
  • Parathyroid Hormone Therapy
  • Selective Estrogen Receptor Modulator (SERM)
  • Rank Ligand Inhibitor
  • Calcitonin
  • Others

Market Segmentation by Geography

  • North America Osteoporosis Drugs Market
    • By drug class
    • By country – U.S. and Rest of North America
  • Europe Osteoporosis Drugs Market
    • By drug class
    • By country – Germany, France, U.K., and Rest of the Europe
  • APAC Osteoporosis Drugs Market
    • By drug class
    • By country – India, China, Japan, and Rest of APAC
  • Rest of the World (RoW) Osteoporosis Drugs Market
    • By drug class